Characteristics and in-hospital mortality of patients with COVID-19 from the first to fifth waves of the pandemic in 2020 and 2021 in the Japanese Medical Data Vision database.
Dexamethasone
Electronic health records
Epidemiology
Severe acute respiratory syndrome coronavirus 2
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
18
10
2022
revised:
15
07
2023
accepted:
24
08
2023
medline:
9
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
We aimed to describe patient characteristics, healthcare utilization, and in-hospital mortality among patients with COVID-19 in Japan across waves. Using a large-scale hospital-based database, we identified patients hospitalized for COVID-19 in the first (January-June 2020), second (June-October 2020), third (October 2020-February 2021), fourth (March-June 2021), and fifth (June-December 2021) waves. We summarized patient characteristics, healthcare utilization, and in-hospital mortality during each wave and performed multivariable logistic regression analyses for in-hospital mortality. From the first to fifth waves, the number of patients (mean age ± standard deviation, years) was 2958 (61.2 ± 22.8), 7981 (55.6 ± 25.3), 18,788 (63.6 ± 22.9), 17,729 (60.6 ± 22.6), and 23,656 (51.2 ± 22.3), respectively. There were 190 (6.4%), 363 (4.5%), 1261 (6.7%), 1081 (6.1%), and 762 (3.2%) in-hospital deaths, respectively. The adjusted odds ratios for in-hospital deaths (95% confidence interval) were 0.78 (0.65-0.95), 0.94 (0.79-1.12), 0.99 (0.84-1.18), 0.77 (0.65-0.92), in the second to fifth waves, respectively, compared with the first wave. In-hospital COVID-19 mortality improved from the first to the second wave; however, during the third and fourth waves, mortality was as serious as in the first wave. Although in-hospital mortality during the fifth wave improved, careful monitoring is needed for upcoming waves, considering changing patient and viral characteristics.
Identifiants
pubmed: 37809807
doi: 10.1016/j.heliyon.2023.e19490
pii: S2405-8440(23)06698-7
pmc: PMC10558584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e19490Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Int J Infect Dis. 2021 Mar;104:742-745
pubmed: 33556610
J Infect. 2021 Apr;82(4):84-123
pubmed: 33152376
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
J Clin Epidemiol. 2006 Oct;59(10):1092-101
pubmed: 16980150
Transbound Emerg Dis. 2021 Mar;68(2):213-215
pubmed: 32892500
Respir Investig. 2021 Nov;59(6):810-818
pubmed: 34565716
Lancet Reg Health West Pac. 2022 Mar 29;23:100442
pubmed: 35359913
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Adv Prev Med. 2021 Oct 08;2021:5807056
pubmed: 34659835
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656
pubmed: 32399563
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
J Epidemiol. 2021 Jan 5;31(1):1-11
pubmed: 33012777